Genitourinary Cancers | Specialty

Pazopanib Less Toxic Than Sunitinib in RCC

August 22nd 2013

Patients with advanced renal cell carcinoma could experience a greater quality of life and the same treatment benefit with pazopanib as opposed to sunitinib.

Taking Care of Business: Regional Urology Offers Consistent Care Despite Tumultuous Times

August 22nd 2013

Change may not always be pleasant, but it is inevitable, and nowhere has that been more evident recently than in US healthcare; however, for the physicians at Regional Urology in Shreveport, Louisiana, these changes are really just business as usual.

The Urologist in the World of Personalized Medicine

August 21st 2013

We should move away from directing therapy based on the primary site of malignancy and focus our efforts on inherent pathways common to the tumors, irrespective of the organ.

Nivolumab Benefits Durable in Three Tumor Types

August 19th 2013

Nivolumab, the most advanced agent in the rapidly developing field of PD-1-targeting cancer immunotherapy, delivered durable clinical benefits across multiple solid tumor types.

Data Support Safety and Benefit of Chemotherapy Before Radical Cystectomy

August 14th 2013

Preoperative chemotherapy was not a predictor of postoperative complications, nor did it increase the length of hospital stays or surgical complications among patients undergoing radical cystectomy for muscle-invasive bladder cancer.

In Some Renal Cell Tumors, Volume More Prognostic Than Size

August 7th 2013

Current T staging for renal cell carcinoma does not capture the full picture of tumor volume, which data have shown to be more predictive of survival and recurrence in certain types of cancer.

Prostate Cancer Gene Test Could Boost Active Surveillance

July 25th 2013

An assay based on tumor genetics showed potential for stratifying risk in prostate cancer patients and aiding selection of men for active surveillance.

Conclusion: Key Take-Away Points and Cardiac Safety

July 1st 2013

Unmet Needs in Renal Cell Carcinoma

July 1st 2013

Immune Checkpoint Inhibition in Renal Cell Carcinoma

July 1st 2013

Novel Agents in Development for Renal Cell Carcinoma

July 1st 2013

INTORSECT Trial: Second-Line Temsirolimus Versus Sorafenib

July 1st 2013

Determining Progression in Renal Cell Carcinoma

July 1st 2013

AXIS Trial: Second-Line Axitinib Versus Sorafenib

July 1st 2013

Frontline Sunitinib Compared to Everolimus in mRCC

July 1st 2013

Utilizing Frontline Bevacizumab in mRCC

July 1st 2013

AGILE Trial: Frontline Axitinib Versus Sorafenib in mRCC

July 1st 2013

PISCES Trial and Patient Treatment Preference in mRCC

July 1st 2013

COMPARZ Trial and Alternate Sunitinib Dosing Schedule

July 1st 2013

Introduction and Review of the COMPARZ Trial in RCC

July 1st 2013